Li Kang Biomedical Co Ltd (6242) — Cash Flow Quality Index
Li Kang Biomedical Co Ltd (6242) has a Cash Flow Quality Index of 2.42x as of December 2025. Operating cash flow of NT$67.23 Million exceeds net income of NT$27.82 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of Li Kang Biomedical Co Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Li Kang Biomedical Co Ltd Cash Flow Quality Index (2002–2025)
Historical Cash Flow Quality Index for Li Kang Biomedical Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 6242 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Li Kang Biomedical Co Ltd (2002–2025)
Year-by-year earnings quality comparison for Li Kang Biomedical Co Ltd. For live market cap and the full company financial profile, see 6242 market cap.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.10x | NT$92.15 Million | NT$83.82 Million | ▲ +29.5% |
| 2024 | 0.85x | NT$65.38 Million | NT$77.02 Million | ▲ +22.1% |
| 2023 | 0.70x | NT$96.74 Million | NT$139.14 Million | ▼ -37.7% |
| 2022 | 1.12x | NT$157.24 Million | NT$140.80 Million | ▲ +17.3% |
| 2021 | 0.95x | NT$60.45 Million | NT$63.48 Million | ▲ +1.4% |
| 2020 | 0.94x | NT$81.67 Million | NT$86.94 Million | ▼ -26.9% |
| 2019 | 1.29x | NT$92.56 Million | NT$72.02 Million | ▼ -6.5% |
| 2018 | 1.38x | NT$105.53 Million | NT$76.74 Million | ▲ +66.3% |
| 2017 | 0.83x | NT$110.61 Million | NT$133.74 Million | ▼ -54.1% |
| 2016 | 1.80x | NT$110.82 Million | NT$61.51 Million | ▲ +49.0% |
| 2015 | 1.21x | NT$63.91 Million | NT$52.85 Million | ▼ -48.7% |
| 2002 | 2.36x | NT$45.87 Million | NT$19.46 Million | — |